Featured Articles

Innovative biotech firm Antengene Corporation Limited has entered into a major global licensing agreement with biopharmaceutical company UCB to advance the development of ATG-201, a…
Read More...

The Ministry of Health, Labour and Welfare has granted orphan drug designation to rilzabrutinib, an investigational oral therapy, for the treatment of IgG4-related disease (IgG4-RD).…
Read More...

Pharmaceutical giant Novo Nordisk has announced a €432 million investment to expand its manufacturing facility in Athlone, Ireland, a move aimed at increasing production capacity for…
Read More...

Novo Nordisk and Vivtex Corporation have announced a strategic partnership to develop next-generation oral biologic medicines targeting obesity, diabetes and related metabolic…
Read More...

IQVIA Holdings Inc. has entered into an agreement to acquire certain drug discovery services assets from Charles River Laboratories, a move designed to expand its early-stage research…
Read More...

GSK plc has agreed to acquire 35Pharma Inc., a privately held Canadian biopharmaceutical company focused on protein-based therapeutics. The deal brings into GSK’s pipeline HS235, an…
Read More...

Gilead Sciences, Inc. has entered into a definitive agreement to acquire Arcellx in a transaction valued at approximately $7.8 billion, strengthening its oncology and cell therapy…
Read More...

AbbVie has unveiled plans to invest $380 million to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago, Illinois campus, expanding…
Read More...

AbbVie has announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for the combination of VENCLEXTA® (venetoclax) and acalabrutinib…
Read More...

Merck & Co., Inc., known as MSD outside the United States and Canada, has entered into a major research and development agreement with Mayo Clinic to apply artificial intelligence…
Read More...

Novartis has announced positive topline results from its pivotal Phase III RemIND trial evaluating oral remibrutinib in patients with chronic inducible urticaria (CIndU), a condition…
Read More...

Boehringer Ingelheim India Private Limited has signed a Memorandum of Understanding (MoU) with National Institute of Pharmaceutical Education and Research, Raebareli (NIPER Raebareli),…
Read More...

Johnson & Johnson has announced plans to invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, further…
Read More...

Biotechnology company Amgen has received authorization from the European Commission for UPLIZNA as an add-on therapy for adults with generalized myasthenia gravis (gMG) who test…
Read More...

Takeda has taken a major step toward introducing a novel treatment for narcolepsy type 1 after the U.S. Food and Drug Administration accepted its New Drug Application and granted…
Read More...

Eisai Co., Ltd. and Shanghai Henlius Biotech have signed an exclusive commercialization and co-exclusive development and manufacturing licensing agreement for the anti-PD-1 antibody…
Read More...

SanegeneBio has entered a global licensing agreement with Genentech, part of the Roche Group, granting the pharmaceutical company exclusive worldwide rights to develop and commercialize…
Read More...

AstraZeneca has strengthened its weight management and metabolic disease pipeline through a new strategic collaboration with CSPC Pharmaceuticals, targeting the development of multiple…
Read More...

AstraZeneca has announced a landmark $15 billion investment in China through 2030, significantly expanding its research, development, and manufacturing capabilities as part of its…
Read More...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending conditional marketing authorisation for Rezurock…
Read More...